drugset
drugset / Trial / NCT01244737

FLT-PET Imaging of Brain Tumors in Children

NCT01244737 ↗

Phase 2 Completed 50 enrolled Frederick Daniel Grant Dana-Farber Cancer Institute · collab
Non-randomizedParallel-groupSingle-blindDiagnostic

Summary

Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is important in the management of these tumors, but current imaging methods have limitations in providing the necessary information for optimal treatment of these patients. The goal of this study is to evaluate the potential utility of positron emission tomography (PET) with 3'-deoxy-3'-\[F-18\] fluorothymidine (18F-FLT) in the medical management of brain tumors in children. Funding source - FDA Office of Orphan Product Development (OOPD)

Timeline

Start
2010-10
Primary completion
2023-02-05
Completion
2023-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FLT Diagnostic / imaging agent 5.55 mbq/kg Intravenous

Indications

brain neoplasm